Senolytic Prodrug Experimental Data with Lysosome-Targeting Linkers

Experimental data from a 2026 study on lysosome-targeted β-galactoside senolytic prodrugs, including Gal-dMor-Gem. The dataset supports the development of targeted drug therapies for cellular senescence. It contains results from six senescent cell models and in vivo mouse studies.

Use Cases

• Analyze senolytic index values (16.1–56.7) across six senescent cell models to compare prodrug efficacy.
• Model drug release kinetics for Gemcitabine (Gem) from prodrugs with different linker modifications.
• Correlate biochemical parameters (body weight, IL-6, lamin B1) with prodrug dosage (0.5 mg/kg, 1.0 mg/kg) in senescent mouse studies.
• Validate preferential accumulation and activation of prodrugs in senescent tissues using biodistribution data.

Strengths

• Data is recent, last updated in March 2026.
• Experimental results are validated across multiple models, including six senescent cell lines and in vivo mouse studies.
• Includes specific, quantified efficacy metrics such as a 2.8- to 3.7-fold improvement in senolytic index over a control.

Limitations

• The dataset is small (3.2 MB), suggesting limited scope or sample size.
• Specific data structure (rows, columns) and sample data are unavailable, hindering immediate analysis.
• Data is focused on specific prodrug compounds, limiting generalizability to other senolytic mechanisms.

Provenance

Source

figshare, authored by Jie Liu.

Collection Method

Experimental data from the design and testing of senolytic prodrugs.

Time Range

Study published in 2026.

Freshness

Last updated 2026-03-24.